Continuing Medical Education Program
Accredited Continuing Education Program Information
The 2023 Annual Meeting is an accredited continuing education activity. Attendees who register for “CME Credits and Certificates” are eligible to claim AMA PRA Category 1 Credit™ for participating in accredited sessions.
The following Annual Meeting session types are not included in the accredited continuing education program: ALCON/Keynote series, Award lectures, Posters, and Special sessions. The complete list of accredited sessions will be posted no later than April 7.
CME credit and certificates processing fee
|ARVO Member/Exhibitor (paid full-meeting access badge)||$99||$119|
|Nonmember/Exhibitor (complimentary full meeting access badge only)||$99||$119|
Physician Accreditation Statement
The Association for Research in Vision and Ophthalmology (ARVO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
ARVO designates this live activity for AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum amount of credit available will be approximately 19-24 credits. The exact amount of credit available will be posted no later than April 7.
International Attendees: The American Medical Association (AMA) has determined that physicians not licensed in the U.S. who participate in CME activities are eligible for AMA PRA Category 1 Credits™.
Statement of Need
Ophthalmic researchers and physicians are many times unaware of and/or have limited exposure to the most recent research advances in vision and ophthalmology. This research continuously evolves toward enhancing the general understanding of the eye and visual systems, which gives rise to new pre-clinical treatment options, and revised standards of practice. Exposure to this new information is a critical first step in enhancing the understanding of basic eye functions and vision disease processes.
The educational design of this activity addresses the needs of basic researchers, clinician-scientists, ophthalmologists, ophthalmology residents, optometrists, post-doctoral fellows, graduate students, PhD candidates, medical students and research assistants/associates involved in the treatment of patients with eye and vision diseases and disorders.
After participating in this CME activity, participants should be able to:
- Discuss the results of basic and clinical ophthalmology investigations and vision research underway, relevant to my area of interest or practice.
- Describe new models and methods being used by researchers and practitioners in eye and vision science.
- Cite ways in which new research data and methods may influence my research and/or practice.
- Discuss prospective advancements in eye and vision research and/or practice.
European Union of Medical Specialists (UEMS) CME/CPD Requirements
European physicians can convert CME credit from the Annual Meeting to meet European Union of Medical Specialists (UEMS) CME/CPD requirements. The American Medical Association has an agreement of mutual recognition of CME credits with the UEMS, the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at email@example.com.
Instructions to receive credit and/or certificates
Learners interested in claiming AMA PRA Category 1 Credits™ or obtain a Certificate of Participation for participating in the Annual Meeting must pay the CME credits and Certificates fee. Payment is collected during the registration process by adding “CME credits and Certificates” as a session. Attendees who do not register for CME before the conclusion of the meeting will not be able to claim and request credit. Learners registered as guests are not eligible to receive CME credit.
Credits and certificates are awarded within our ARVOLearn platform. CME registrants will receive an email with instructions prior to the start of the Annual Meeting or within two business days of your purchase (whichever is later). All requests for credit must be submitted no later than 11:59pm U.S. Eastern Time on Friday, Aug. 30, 2023.
Certificate of Participation
ARVO is accredited to offer AMA PRA Category 1 Credits™ to physicians. All other participants in the CME program may receive a Certificate of Participation that documents the number of CME hours attended* by following the same instructions listed above and paying the CME credits and certificates fee.*Some accrediting agencies may award equivalent Continuing Education (CE) credit when presented with a Certificate of Participation from an activity that offered AMA PRA Category 1 Credit™. Check with your accrediting agency for information.Certificate of AttendanceCertificates of attendance are available free to all attendees. These certificates state that one has attended the Annual Meeting; but does not offer credit tracking. They will be available for pick-up onsite at the meeting registration desk and ARVO Central in the exhibit hall.
5515 Security Lane, Suite 500
Rockville, Md. 20852, USA
Email: firstname.lastname@example.org, p. +188.8.131.5200
The Annual Meeting provides a forum for the open exchange and discussion of research results and scientific advancements in the field of ophthalmology; however, ARVO makes no representation or warranty as to the truth, originality, or accuracy of the information presented at the meeting or in materials distributed in connection with them. Nor are the views expressed by the individual speakers necessarily the views of ARVO. ARVO supports the ACCME’s policy on evidence-based content and encourages faculty to adhere to these standards when planning a presentation.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this meeting is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclaimer off-label use
The Annual Meeting may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ARVO does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Disclosure of Relevant Financial Relationships
ARVO requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose all financial relationships with any ineligible company within the last 24 months. All identified relevant financial relationships are thoroughly vetted by ARVO for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
All relevant financial relationships have been mitigated by ARVO. ARVO considers presenting authors, not co-authors, to be in control of the educational content. It is ARVO’s policy and traditional scientific publishing practice to acknowledge all people contributing to the research, regardless of CME control of the live presentation of that content. ARVO may collect and publish disclosures from co-authors although they do not have control of the CME content.
Disclosures for all individuals involved in planning and managing this accredited CE activity are listed here with their relevant disclosure information. Disclosure information for presenters and session moderators will be provided within a session disclosure slide(s), prior to the start of the session and their respective presentations.
The following individuals on the Annual Meeting Program Committee (AMPC) reported no relevant financial relationships.
Manuela Bartoli, PhD; Catherine Cheng, PhD; Carol Cheung, PhD; Yuen Ping Toco Chui, PhD; Catherine Cukras, MD, PhD; Lauren Dalvin, MD; Xingjun Fan, PhD; Sabine Fuhrmann, PhD; Vijaya Gothwal, PhD; Stephanie Hagstrom, PhD; J Heur, MD, PhD; Robert Hufnagel, MD, PhD; Pirro Hysi, MD, PhD; Sudha Iyengar, PhD; Vishal Jhanji, MD; Chea-su Kee, PhD; Krista Kelly, PhD; Vikas Khetan, MD, FRCS Ed, Frcs glad, FRC oph; Raghu Krishnamoorthy, PhD; Ashok Kumar, PhD; Van Lansingh, MD, PhD, MBA; Sun Young Lee, MD, PhD; Paloma Liton, PhD; Juliet Moncaster, PhD; Yuki Morizane, MD, PHD; Michael Pircher, Assoc. Prof.; Christophe Ribelayga, PhD; Danielle Robertson, OD, PhD; Elizabeth Rossin, MD, PHD; Tiffany Schmidt, PhD; Elena Semina, PhD; Anthony St. Leger, PhD; Dorota Stankowska, PhD; Daniel Sun, PhD; Budd Tucker, PhD; Ruth van Nispen, MSc, MA, PhD; Kyung Chul Yoon, MD, PhD; Robert Zawadzki, PhD; Yan Zhang, PhD
The following individuals on the Continuing Medical Education Committee (CME) reported no relevant financial relationships.
Parisa Emami, MD, MPH; Shilpa Kodati, MBBS; Wendy Liu, MD, PhD; Yannis Paulus, MD; Sangly Srinivas, PhD; Mary Whitman, MD, PhD
The following activity managers reported no relevant financial relationships.
Isabel "Regina" Borkoski, Lancey Cowan, Kathy Cox, and Cathy Conley
The following clinical content reviewers reported no relevant financial relationships.
Lindsay Scott, PT, DPT, ATC
The following reported financial relationships:
|Jesse Berry, MD||AMPC||Biotissue: (C); Castle Biosciences: (C); Patent Aqueous humor cell free DNA for diagnostic and Prognostic evaluation of Ophthalmic Disease (P)|
|Julia Busik, PhD||AMPC||Ceramedix, Inc.: (C, P)|
|Aurelie Calabrese, PhD||AMPC||Precision Vision: (P)|
|Ranjay Chakraborty, PhD||AMPC||Essilor: (F); CooperVision: (F)|
|Edward Chaum, MD, PhD||AMPC||Baxter/HillRom: (C, R, S); Luna: (C, S); 1-800 Contacts: (C, R, S); Plexitome Medical: (O, I, P, S)|
|Ching-Yu Cheng, MD, MPH, PhD||AMPC||Medi-Wahle, Inc: (C); Santen: (R)|
|Qi Cui, MD, PhD||AMPC||Neuraly, Inc.: (F)|
|Joshua Ehrlich, MD, MPH||AMPC||MetLife: (C)|
|Gerhard Garhöfer, MD||AMPC||Apis:(C); Böhringer-Ingelheim: (C); Croma: (C); EyeD: (C); Kiora: (C); Novaliq: (C); Panoptes: (C); Redwood: (C); Santen: (C); Sintetica: (C); Thea: (C)|
|Pedram Hamrah, MD||AMPC||Dompe: (F, C); Noveome: (F, C); Claris: (F); Coopervision: (F); Novartis: (F, C); Ocular Therapeutix: (F); OKYO: (F); Kala: (C); Novaliq: (C); Sanofi: (C); Several parents in area of neurotrophic keratitis and inflammation (P)|
|Lynn Hassman, MD, PhD||AMPC||Pfizer: (F); Gilead: (F); Santen: (F) Pfizer: (F); Gilead: (F); Santen: (F)|
|Thomas Johnson III, MD, PhD||AMPC||Abbvie: (C); Perfuse Therapeutics: (F); InjectSense: (F); iCare USA: (F); Alcon: (F); National Eye Institute: (F)|
|Shizuka Koh, MD, PhD||AMPC||Alcon: (R); Bausch + Lomb: (R); Cooper Vision: (R); Johnson & Johnson: (R); Menicon: (R); Novartis: (R); Oculus: (C, R); Ophtecs: (R); Otsuka: (R); Rohto: (F, R); Sanofi: (R); Santen: (R); SEED: (F, R); Senju: (R); Sumitomo Pharma: (R)|
|David Krizaj, PhD||AMPC||TMClear: (P,S, O)|
|Anthony Kuo, MD||AMPC||Leica: (P); Johnson & Johnson: (F)|
|VIvian Lee, MD||AMPC||GSK (C)|
|Yan Li, PhD||AMPC||Visionix USA: (F, P, R)|
|Jason Meyer, PhD||AMPC||Wisconsin Alumni Research Foundation: (P); Stoke Therapeutics: (C)|
|Jessica Morgan, PhD||AMPC||AGTC: (F); US Patent 8226236: ()P); US Patent App. 16/389,942: (P)|
|Koji Nishiguchi, MD, PhD||AMPC||Alcon: (R, F); Bayer: (R, F); JCR Pharma: (P, F); Novartis: (C, R, F); Santen Pharma: (R, F); Kowa Pharma: (R, F); Senju Pharma: (R, F, C); Wakamoto Pharma: (F); HOYA: (F); Tomey: (F); AMO Japan: (F); Chugai Pharma: (R); Nitten Phrama: (F); Janssen Pharma: (R, F)|
|Mark Petrash, PhD||AMPC||BELLUS Health Inc.: (C)|
|Christina Prescott, MD, PhD||AMPC||Johnson and Johnson Vision: (C)|
|Christian Prünte, MD||AMPC||Alcon: (C, R); Apellis: (C, R); Bayer: (C, R); Novartis: (C, R); Oertli: (C, R); Opharmic: (C); Roche: (C, R)|
|Francisco J Rodriguez, MD||AMPC||Abbvie: (C); Bayer: (C, R); Iridex: (C, R); Novartis: (C, R, F); Roche: (C, R)|
|Jos Rozema, MSc, PhD||AMPC||Azalea Vision: (C)|
|Brian Samuels, MD, PhD||AMPC||Heidelberg Engineering, Inc: (F)|
|Rebecca Sappington, BS, MS, PhD||AMPC||Cyclerion Therapeutics: (F)|
|Alexander Schuster, MD, MSc||AMPC||Abbvie: (F); Bayer Healthcare: (F); Heidelberg Engineering: (F); Santen: (F); Novartis: (F)|
|Dimitra Skondra, MD, PhD||AMPC||Allergan: (C); Biogen: (C); Alimera Science: (C); Focuscope: (C); LaGrippe Research: (C); SITC: (R)|
|Olaf Strauss, Univ.-Prof. PhD||AMPC||Bayer Healthcare: (C); Novartis: (R); Abbivie: (R)|
|Mervyn Thomas, MBChB, FRCOphth, PhD||AMPC||Leica MicroSystems: (C)|
|Fuensanta Vera-Diaz, PhD, OD||AMPC||Essilor International: (C); Vyluma, Inc.: (F); EssilorLuxottica: (F)|
|Brian Vohnsen, PhD||AMPC||Johnson & Johnson Vision: (C, F); iKey: (C); Alcon Laboratories Ireland (F)|
|Lihteh Wu, MD||AMPC||Quantel Medical: (C); Bayer: (C); Roche: (C)|
|Yoshiaki Yasuno, PhD||AMPC||Topcon: (F); Nikon: (F); Kao: (F); Yokogawa: (F); Skytechnology: (F)|
|Gui-shuang Ying, PhD||AMPC||Atsena Therapeutics, Inc: (C); Stoke Therapeutics, Inc.: (C); Ziemer Ophthalmic Systems AG: (C); Apellis Pharmaceuticals, Inc.: (C); Applied Clinical Intelligence LLC: (C)|
|Patrick Yu-Wai-Man, BMedSci (Hons), MBBS (Hons), PhD, FRCPath, FRCOphth||AMPC||GenSight Biologics: (C); Chiesi: (C); Transine Therapeutics: (C); Stoke Therapeutics: (C); PYC Therapeutics: (C)|
|Thomas Ach, MD, FEBO||CME||Apellis Pharmaceutical: (R); Roche: (R); Novartis: (R, F); Bayer: (R); Heidelberg Engineering: (R); MacRegen Inc.: (I)|
|Ron Adelman, MD, MPH, MBA||CME||Tesseract: (C); Johnson & Johnson/Jenssen: (C)|
|Natasha Kolomeyer, MD||CME||AbbVie/Allergan: (F, C); Guardion Health Services Inc.: (F); Equinox: (F); Nicox: (F); Olleyes: (F); Santen: (F); Glaukos: (F); Diopsys: (F); Aerie: (F);|
|Louis Pasquale, MD||CME||Eyenovia: (C); Twenty Twenty: (C); Skye Biosciences: (C)|